Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for OneSource Specialty Pharma's Equity-to-Asset or its related term are showing as below:
NSE:ONESOURCE'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.3 Med: 0.71 Max: 0.78
Current: 0.71
During the past 4 years, the highest Equity to Asset Ratio of OneSource Specialty Pharma was 0.78. The lowest was 0.30. And the median was 0.71.
NSE:ONESOURCE's Equity-to-Asset is ranked better than 53.99% of 1415
companies
in the Biotechnology industry
Industry Median: 0.68
vs NSE:ONESOURCE: 0.71
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
OneSource Specialty Pharma Equity-to-Asset Related Terms
OneSource Specialty Pharma Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ONESOURCE vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, OneSource Specialty Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OneSource Specialty Pharma Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OneSource Specialty Pharma's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where OneSource Specialty Pharma's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
OneSource Specialty Pharma's Equity to Asset Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OneSource Specialty Pharma (NSE:ONESOURCE) has a Equity-to-Asset of 0.00 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OneSource Specialty Pharma and its competitors. Over the past decade, OneSource Specialty Pharma's Equity-to-Asset has ranged from 0.30 to 0.78. According to the industry distribution chart, OneSource Specialty Pharma ranks #651 out of 1415 companies in the Biotechnology industry, placing it in the top 46%.
Is OneSource Specialty Pharma's Equity-to-Asset too high?
OneSource Specialty Pharma's current Equity-to-Asset is 0.00. Over the past 10 years, this metric has ranged from a low of 0.30 to a high of 0.78. Based on the distribution chart, OneSource Specialty Pharma ranks #651 out of 1415 companies in the Biotechnology industry, which is above the industry midpoint. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, OneSource Specialty Pharma ranks #651 out of 1415 companies for Equity-to-Asset. This puts OneSource Specialty Pharma in the upper half of its industry. The industry median Equity-to-Asset is 0.68. Historically, OneSource Specialty Pharma's own Equity-to-Asset has ranged from 0.30 to 0.78 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,415 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on OneSource Specialty Pharma and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OneSource Specialty Pharma's current Equity-to-Asset is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (NSE:ONESOURCE) has a current Equity-to-Asset of 0.00. The current Equity-to-Asset is 0.00. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For OneSource Specialty Pharma (NSE:ONESOURCE), the current Equity-to-Asset is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score
Get the complete analysis for NSE:ONESOURCE
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ONESOURCE has been successfully added to your 
